Search

Your search keyword '"Cho, Eun Kyung"' showing total 41 results
Start Over Author "Cho, Eun Kyung" Publication Year Range Last 3 years
41 results on '"Cho, Eun Kyung"'

1. The forb-flex method for odd coloring and proper conflict-free coloring of planar graphs

Author

Anderson, James, Chau, Herman, Cho, Eun-Kyung, Crawford, Nicholas, Hartke, Stephen G., Heath, Emily, Henderschedt, Owen, Kwon, Hyemin, and Zhang, Zhiyuan

Subjects
Mathematics - Combinatorics
Abstract

We introduce a new tool useful for greedy coloring, which we call the forb-flex method, and apply it to odd coloring and proper conflict-free coloring of planar graphs. The odd chromatic number, denoted $\chi_{\mathsf{o}}(G)$, is the smallest number of colors needed to properly color $G$ such that every non-isolated vertex of $G$ has a color appearing an odd number of times in its neighborhood. The proper conflict-free chromatic number, denoted $\chi_{\mathsf{PCF}}(G)$, is the smallest number of colors needed to properly color $G$ such that every non-isolated vertex of $G$ has a color appearing uniquely in its neighborhood. Our new tool works by carefully counting the structures in the neighborhood of a vertex and determining if a neighbor of a vertex can be recolored at the end of a greedy coloring process to avoid conflicts. Combining this with the discharging method allows us to prove $\chi_{\mathsf{PCF}}(G) \leq 4$ for planar graphs of girth at least 11, and $\chi_{\mathsf{o}}(G) \leq 4$ for planar graphs of girth at least 10. These results improve upon the recent works of Cho, Choi, Kwon, and Park., Comment: 32 pages, 11 figures

Published
2024

2. On the interval coloring impropriety of graphs

Author

Carr, MacKenzie, Cho, Eun-Kyung, Crawford, Nicholas, Iršič, Vesna, Pai, Leilani, and Robinson, Rebecca

Subjects
Mathematics - Combinatorics, 05C15
Abstract

An improper interval (edge) coloring of a graph $G$ is an assignment of colors to the edges of $G$ satisfying the condition that, for every vertex $v \in V(G)$, the set of colors assigned to the edges incident with $v$ forms an integral interval. An interval coloring is $k$-improper if at most $k$ edges with the same color all share a common endpoint. The minimum integer $k$ such that there exists a $k$-improper interval coloring of the graph $G$ is the interval coloring impropriety of $G$, denoted by $\mu_{int}(G)$. In this paper, we provide a construction of an interval coloring of a subclass of complete multipartite graphs. This provides additional evidence to the conjecture by Casselgren and Petrosyan that $\mu_{int}(G)\leq 2$ for all complete multipartite graphs $G$. Additionally, we determine improved upper bounds on the interval coloring impropriety of several classes of graphs, namely 2-trees, iterated triangulations, and outerplanar graphs. Finally, we investigate the interval coloring impropriety of the corona product of two graphs, $G\odot H$., Comment: 17 pages, 8 figures, 7 tables

Published
2023

3. Domination of subcubic planar graphs with large girth

Author

Cho, Eun-Kyung, Culver, Eric, Hartke, Stephen G., and Iršič, Vesna

Subjects
Mathematics - Combinatorics
Abstract

Since Reed conjectured in 1996 that the domination number of a connected cubic graph of order $n$ is at most $\lceil \frac13 n \rceil$, the domination number of cubic graphs has been extensively studied. It is now known that the conjecture is false in general, but Henning and Dorbec showed that it holds for graphs with girth at least $9$. Zhu and Wu stated an analogous conjecture for 2-connected cubic planar graphs. In this paper, we present a new upper bound for the domination number of subcubic planar graphs: if $G$ is a subcubic planar graph with girth at least 8, then $\gamma(G) < n_0 + \frac{3}{4} n_1 + \frac{11}{20} n_2 + \frac{7}{20} n_3$, where $n_i$ denotes the number of vertices in $G$ of degree $i$, for $i \in \{0,1,2,3\}$. We also prove that if $G$ is a subcubic planar graph with girth at least 9, then $\gamma(G) < n_0 + \frac{13}{17} n_1 + \frac{9}{17} n_2 + \frac{6}{17} n_3$., Comment: 26 pages, 35 figures

Published
2023

5. Independent domination versus packing in subcubic graphs

Author

Cho, Eun-Kyung and Kim, Minki

Subjects
Mathematics - Combinatorics
Abstract

In 2011, Henning, L\"{o}wenstein, and Rautenbach observed that the domination number of a graph is bounded from above by the product of the packing number and the maximum degree of the graph. We prove a stronger statement in subcubic graphs: the independent domination number is bounded from above by three times the packing number., Comment: 9 pages, 3 figures

Published
2023

7. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Author

Cho, Byoung Chul, Kim, Dong-Wan, Spira, Alexander I, Gomez, Jorge E, Haura, Eric B, Kim, Sang-We, Sanborn, Rachel E, Cho, Eun Kyung, Lee, Ki Hyeong, Minchom, Anna, Lee, Jong-Seok, Han, Ji-Youn, Nagasaka, Misako, Sabari, Joshua K, Ou, Sai-Hong Ignatius, Lorenzini, Patricia, Bauml, Joshua M, Curtin, Joshua C, Roshak, Amy, Gao, Grace, Xie, John, Thayu, Meena, Knoblauch, Roland E, and Park, Keunchil

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Lung, Lung Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prospective Studies, Protein Kinase Inhibitors, Mutation, Aniline Compounds, ErbB Receptors, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) often develop resistance to current standard third-generation EGFR tyrosine kinase inhibitors (TKIs); no targeted treatments are approved in the osimertinib-relapsed setting. In this open-label, dose-escalation and dose-expansion phase 1 trial, the potential for improved anti-tumor activity by combining amivantamab, an EGFR-MET bispecific antibody, with lazertinib, a third-generation EGFR TKI, was evaluated in patients with EGFR-mutant NSCLC whose disease progressed on third-generation TKI monotherapy but were chemotherapy naive (CHRYSALIS cohort E). In the dose-escalation phase, the recommended phase 2 combination dose was established; in the dose-expansion phase, the primary endpoints were safety and overall response rate, and key secondary endpoints included progression-free survival and overall survival. The safety profile of amivantamab and lazertinib was generally consistent with previous experience of each agent alone, with 4% experiencing grade ≥3 events; no new safety signals were identified. In an exploratory cohort of 45 patients who were enrolled without biomarker selection, the primary endpoint of investigator-assessed overall response rate was 36% (95% confidence interval, 22-51). The median duration of response was 9.6 months, and the median progression-free survival was 4.9 months. Next-generation sequencing and immunohistochemistry analyses identified high EGFR and/or MET expression as potential predictive biomarkers of response, which will need to be validated with prospective assessment. ClinicalTrials.gov identifier: NCT02609776 .

Published
2023

8. Brooks-type theorems for relaxations of square colorings

Author

Cho, Eun-Kyung, Choi, Ilkyoo, Kwon, Hyemin, and Park, Boram

Subjects
Mathematics - Combinatorics
Abstract

The following relaxation of proper coloring the square of a graph was recently introduced: for a positive integer $h$, the proper $h$-conflict-free chromatic number of a graph $G$, denoted $\chi_{pcf}^h(G)$, is the minimum $k$ such that $G$ has a proper $k$-coloring where every vertex $v$ has $\min\{deg_G(v),h\}$ colors appearing exactly once on its neighborhood. Caro, Petru\v{s}evski, and \v{S}krekovski put forth a Brooks-type conjecture: if $G$ is a graph with $\Delta(G)\ge 3$, then $\chi_{pcf}^1(G)\leq \Delta(G)+1$. The best known result regarding the conjecture is $\chi_{pcf}^1(G)\leq 2\Delta(G)+1$, which is implied by a result of Pach and Tardos. We improve upon the aforementioned result for all $h$, and also enlarge the class of graphs for which the conjecture is known to be true. Our main result is the following: for a graph $G$, if $\Delta(G) \ge h+2$, then $\chi_{pcf}^h(G)\le (h+1)\Delta(G)-1$; this is tight up to the additive term as we explicitly construct infinitely many graphs $G$ with $\chi_{pcf}^h(G)=(h+1)(\Delta(G)-1)$. We also show that the conjecture is true for chordal graphs, and obtain partial results for quasi-line graphs and claw-free graphs. Our main result also improves upon a Brooks-type result for $h$-dynamic coloring., Comment: 20 pages, 1 figure

Published
2023

9. Relaxation of Wegner's Planar Graph Conjecture for maximum degree 4

Author

Cho, Eun-Kyung, Choi, Ilkyoo, and Lidický, Bernard

Subjects
Mathematics - Combinatorics
Abstract

The famous Wegner's Planar Graph Conjecture asserts tight upper bounds on the chromatic number of the square $G^2$ of a planar graph $G$, depending on the maximum degree $\Delta(G)$ of $G$. The only case that the conjecture is resolved is when $\Delta(G)=3$, which was proven to be true by Thomassen, and independently by Hartke, Jahanbekam, and Thomas. For $\Delta(G)=4$, Wegner's Planar Graph Conjecture states that the chromatic number of $G^2$ is at most 9; even this case is still widely open, and very recently Bousquet, de Meyer, Deschamps, and Pierron claimed an upper bound of 12. We take a completely different approach, and show that a relaxation of properly coloring the square of a planar graph $G$ with $\Delta(G)=4$ can be achieved with 9 colors. Instead of requiring every color in the neighborhood of a vertex to be unique, which is equivalent to a proper coloring of $G^2$, we seek a proper coloring of $G$ such that at most one color is allowed to be repeated in the neighborhood of a vertex of degree 4, but nowhere else., Comment: 9 pages

Published
2022

10. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor[FIGURE DASH]Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Author

Yang, James Chih-Hsin, Lee, Dae Ho, Lee, Jong-Seok, Fan, Yun, de Marinis, Filippo, Iwama, Eiji, Inoue, Takako, Rodríguez-Cid, Jerónimo, Zhang, Li, Yang, Cheng-Ta, de la Mora Jimenez, Emmanuel, Zhou, Jianying, Pérol, Maurice, Lee, Ki Hyeong, Vicente, David, Ichihara, Eiki, Riely, Gregory J., Luo, Yiwen, Chirovsky, Diana, Pietanza, M. Catherine, Bhagwati, Niyati, Lu, Shun, Joseph Boyer, Michael, Hui, Rina, Wong, Mark, Mant, Andrew, Parente, Phillip, John, Thomas, Parakh, Sagun, Castro, Gilberto, Jr, Werutsky, Gustavo, de Azevedo, Sergio Jobim, Andre Franke, Fabio, De Almeida Rego, Joilda Batista, Martins De Marchi, Pedro Rafael, Dix Junqueira, Gustavo, Maris Peria, Fernanda, Brust, Leandro, Cheema, Parneet, Doherty, Mark, Parmar, Ambika, Menjak, Ines B., Leighl, Natasha B., Agulnik, Jason, Lu, Shun, Han, Zhigang, Cui, Jiuwei, Zhang, Li, Cheng, Ying, Chen, Gongyan, Zhang, Helong, Yao, Yu, Hu, Chengping, Wang, Qiming, Zhang, Xin, Zhang, Yong, Zhou, Jianying, Ying, Kejing, Fan, Yun, Wang, Yan, Wang, Ziping, Feng, Jifeng, Du, YingYing, Wu, Lin, Huang, Cheng, Zhou, Xiangdong, Perol, Maurice, Domont, Julien, Lamour, Corinne, Dutilh, Julien, Oulkhouir, Youssef, Westeel, Virginie, Carmier, Delphine, Coudert, Bruno, Lagrange, Aurelie, Spaeth, Dominique, Ropert, Stanislas, Christoph, Daniel C., Kern, Jens, Kopp, Hans-Georg, Griesinger, Frank, Wiewrodt, Rainer, Wermke, Martin, Wesseler, Claas, Mueller, Annette, Vogel, Gunther, Lee, Victor, James Ho, Chung Man, Oscar Chan, Siu Hong, Hung Lo, Sing, Jonathan Nyaw, Shi Feng, Jacky Li, Yu Chung, Bar, Jair, Gottfried, Maya, Dudnik, Julia, Zer, Alona, Moskovitz, Mor, Wollner, Mirjana, Rotem, Ofer, Shamai, Sivan, Asna, Noam, Kamel, Mhameed, Novello, Silvia, Di Costanzo, Francesco, Doni, Laura, Mazzoni, Francesca, Ferrau, Francesco, de Marinis, Filippo, Tonini, Giuseppe, Galetta, Domenico, Piantedosi, Francovito, Vitiello, Fabiana, Kirita, Keisuke, Yoh, Kiyotaka, Takahashi, Toshiaki, Ohe, Yuichiro, Hattori, Yoshihiro, Okamoto, Isamu, Kurata, Takayasu, Yoshioka, Hiroshige, Saka, Hideo, Oki, Masahide, Kato, Terufumi, Tanaka, Hiroshi, Kumagai, Toru, Inoue, Takako, Hida, Toyoaki, Horio, Yoshitsugu, Teraoka, Shunsuke, Ichihara, Eiki, Kishi, Kazuma, Takaya, Hisashi, Takai, Daiya, Kozuki, Toshiyuki, Kasahara, Kazuo, Tambo, Yuichi, Hosomi, Yukio, Kondo, Masashi, Ichiki, Masao, Takeoka, Hiroaki, de la Mora Jimenez, Emmanuel, Hernandez, Carlos Alberto, Rodriguez Cid, Jeronimo Rafael, Rodriguez, Oscar Gerardo Arrieta, Han, Ji-Youn, Min, Young Joo, Kim, Dong-Wan, Park, Keunchil, Lee, Se-Hoon, Lee, Ki Hyeong, Lee, Jong-Seok, Kang, Jin Hyoung, Lee, Dae Ho, Cho, Eun Kyung, Carcereny, Enric, Lopez, Pilar Garrido, Tarruella, Margarita Majem, Rodriguez, Luis Paz-Ares, Vicente Baz, David, Font, Enriqueta Felip, Cobo-Dols, Manuel, Ekman, Simon, Bergman, Bengt, Ohman, Ronny, Vikstrom, Anders, Yang, Chih-Hsin, Chiu, Chao-Hua, Huang, Hsu-Ching, Yang, Cheng-Ta, Su, Jian, Chang, Gee-Chen, Yang, Tsung-Ying, Hsia, Te-Chun, Su, Wu-Chou, Wu, Shang-Yin, Wang, Chin-Chou, Lee, Kang-Yun, Lin, Sheng-Hao, Lin, Chih-Bin, Lee, Jih-Hsiang, Huang, Chun-Yao, Ahmed, Samreen, Newsom-Davis, Thomas, Baijal, Shobhit, Brock, Juliet, Zaki, Kam, Shamash, Jonathan, Papadatos-Pastos, Dionysis, Jain, Pooja, Jane Mackean, Melanie, Kendall, Stephan DiSean, Anderson, Ian, Costin, Dan, Hall, Richard, Campbell, Nicholas, Khan, Saad, Dowell, Jonathan, Mashru, Sandeep, Menon, Smitha, Raza, Ahmad, Ge, Li, Riely, Gregory J., Seetharamu, Nagashree, Stampleman, Laura, Subramanian, Janakiraman, Wender, Donald B., Natale, Ronald B., Zhu, Viola, Ignatius Ou, Sai-Hong, Sanborn, Rachel, and Evangelist, Makenzi C.

Published
2024
Full Text
View/download PDF

13. Proper conflict-free coloring of sparse graphs

Author

Cho, Eun-Kyung, Choi, Ilkyoo, Kwon, Hyemin, and Park, Boram

Subjects
Mathematics - Combinatorics
Abstract

A {\it proper conflict-free $c$-coloring} of a graph is a proper $c$-coloring such that each non-isolated vertex has a color appearing exactly once on its neighborhood. This notion was formally introduced by Fabrici et al., who proved that planar graphs have a proper conflict-free 8-coloring and constructed a planar graph with no proper conflict-free 5-coloring. Caro, Petru\v{s}evski, and \v{S}krekovski investigated this coloring concept further, and in particular studied upper bounds on the maximum average degree that guarantees a proper conflict-free $c$-coloring for $c\in\{4,5,6\}$. Along these lines, we completely determine the threshold on the maximum average degree of a graph $G$, denoted $mad(G)$, that guarantees a proper conflict-free $c$-coloring for all $c$ and also provide tightness examples. Namely, for $c\geq 5$ we prove that a graph $G$ with $mad(G)\leq \frac{4c}{c+2}$ has a proper conflict-free $c$-coloring, unless $G$ contains a $1$-subdivision of the complete graph on $c+1$ vertices. When $c=4$, we show that a graph $G$ with $mad(G)<\frac{12}{5}$ has a proper conflict-free $4$-coloring, unless $G$ contains an induced $5$-cycle. In addition, we show that a planar graph with girth at least 5 has a proper conflict-free $7$-coloring., Comment: 15 pages, 2 figures

Published
2022

14. Odd coloring of sparse graphs and planar graphs

Author

Cho, Eun-Kyung, Choi, Ilkyoo, Kwon, Hyemin, and Park, Boram

Subjects
Mathematics - Combinatorics
Abstract

An {\it odd $c$-coloring} of a graph is a proper $c$-coloring such that each non-isolated vertex has a color appearing an odd number of times on its neighborhood. This concept was introduced very recently by Petru\v sevski and \v Skrekovski and has attracted considerable attention. Cranston investigated odd colorings of graphs with bounded maximum average degree, and conjectured that every graph $G$ with $mad(G)\leq \frac{4c-4}{c+1}$ has an odd $c$-coloring for $c\geq 4$, and proved the conjecture for $c\in\{5, 6\}$. In particular, planar graphs with girth at least $7$ and $6$ have an odd $5$-coloring and an odd $6$-coloring, respectively. We completely resolve Cranston's conjecture. For $c\geq 7$, we show that the conjecture is true, in a stronger form that was implicitly suggested by Cranston, but for $c=4$, we construct counterexamples, which all contain $5$-cycles. On the other hand, we show that a graph $G$ with $mad(G)<\frac{22}{9}$ and no induced $5$-cycles has an odd $4$-coloring. This implies that a planar graph with girth at least 11 has an odd $4$-coloring. We also prove that a planar graph with girth at least 5 has an odd $6$-coloring., Comment: 12 pages

Published
2022

15. Independent domination of graphs with bounded maximum degree

Author

Cho, Eun-Kyung, Kim, Jinha, Kim, Minki, and Oum, Sang-il

Subjects
Mathematics - Combinatorics
Abstract

An independent dominating set of a graph, also known as a maximal independent set, is a set $S$ of pairwise non-adjacent vertices such that every vertex not in $S$ is adjacent to some vertex in $S$. We prove that for $\Delta=4$ or $\Delta\ge 6$, every connected $n$-vertex graph of maximum degree at most $\Delta$ has an independent dominating set of size at most $(1-\frac{\Delta}{\lfloor\Delta^2/4\rfloor+\Delta})(n-1)+1$. In addition, we characterize all connected graphs having the equality and we show that other connected graphs have an independent dominating set of size at most $(1-\frac{\Delta}{ \lfloor\Delta^2/4\rfloor+\Delta})n$., Comment: 14 pages

Published
2022
Full Text
View/download PDF

18. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Author

Sevelda, Paul, Haslbauer, Ferdinand, Penzinger, Monika, Öhler, Leopold, Tinchon, Christoph, Greil, Richard, Heibl, Sonja, Bartsch, Rupert, Wette, Viktor, Singer, Christian F., Pasterk, Claudia, Helfgott, Ruth, Pristauz-Telsnigg, Gunda, Stöger, Herbert, Weltermann, Angsar, Egle, Daniel, Thiel, Irene, Fuchs, David, Rumpold, Holger, Strasser-Weippl, Kathrin, Rautenberg, Beate, Müller, Volkmar, Schmidt, Marcus, Paepke, Stefan, Aydogdu, Mustafa, Thomssen, Christoph, Rom, Joachim, Mau, Christine, Fasching, Peter, Göhring, Uwe-Jochen, Kühn, Thorsten, Noeding, Stefanie, Kümmel, Sherko, Hackmann, John, Stickeler, Elmar, Joshi, Abhishek, Dewar, Joanna, Friedlander, Michael, Phillips, Kelly-Anne, Antill, Yoland, Woodward, Natasha, Abdi, Ehtesham, Tiley, Susan, George, Mathew, Boadle, David, Goodwin, Annabel, van der Westhuizen, Andre, Kannourakis, George, Murray, Nicholas, McCarthy, Nicole, Kroep, Judith, de Boer, Maaike, Heijns, Joan, Jager, Agnes, Erdkamp, Franciscus, Bakker, Sandra, Sonke, Gabe S., Sami, Amer, Mackey, John, Prady, Catherine, Eisen, Andrea, Desbiens, Christine, Patocskai, Erica, Ferrario, Cristiano, Gelmon, Karen, Bordeleau, Louise, Chalchal, Haji, Niraula, Saroj, ido wolf, Senkus, Elżbieta, Duhoux, François, Randal d’Hondt, Luce, Sylvie, Roodenbeke, Daphné t’Kint de, Papadimitriou, Konstantinos, Borms, Marleen, Quaghebeur, Claire, Jacot, William, Brain, Etienne, Venat-Bouvet, Laurence, Lortholary, Alain, Nowecki, Zbigniew, Cardoso, Fátima, Hayward, Richard, Bella, Santiago, Lazzaro, Mauricio Fernández, Pilnik, Norma, Fein, Luis E., Blajman, Cesar, Lerzo, Guillermo, Varela, Mirta, Zarba, Juan Jose, Kaen, Diego, Constanzo, Maria Victoria, Tio, Joke, Siggelkow, Wulf, Jackisch, Christian, Grischke, Eva Maria, Zahm, Dirk, Tato-Varela, Sara, Schmatloch, Sabine, Klare, Peter, Stefek, Andrea, Rhiem, Kerstin, Hoffmann, Oliver, Deryal, Mustafa, Gröll, Isolde, Ledwon, Peter, Uleer, Christoph, Krabisch, Petra, Potenberg, Jochem, Darsow, Maren, Park-Simon, Tjoung-Won, Höffkes, Heinz-Gert, Emde, Till-Oliver, Graffunder, Gerd, Tomé, Oliver, Forstmeyer, Dirk, Terhaag, Jürgen, Salat, Christoph, Kast, Karin, Weniger, Steffi, Schreiber, Carsten, Heinrich, Bernhard, Dieterich, Max, Wüllner, Michaela Penelope, Conejero, Raquel Andrés, García Sáenz, José Ángel, Martinez, Lourdes Calvo, Lanza, Angels Arcusa, Murillo, Serafín Morales, Carrasco, Fernando Henao, Tormo, Salvador Blanch, López, Isabel Álvarez, Delgado Mingorance, Juan Ignacio, Gomez, Elena Álvarez, Santisteban, Marta, Jurado, Josefina Cruz, Quiroga, Vanesa, Borrego, Manuel Ruiz, Martínez de Dueñas, Eduardo, Alés Martínez, Jose Enrique, De la Haba, Juan, Jañez, Noelia Martínez, Lescure, Álvaro Rodríguez, Torres, Antonio Antón, Crusades, Gema Llort, González-Santiago, Santiago, Aragones, Antonia Marquez, Ortega, Ana Laura, Molins, Agusti Barnadas, Chacón López-Muñiz, José Ignacio, Jiménez, Miguel Martín, Bertrán, Ana Santaballa, Rodríguez, César, Cortijo, Lucía González, Cretella, Elisabetta, Cortesi, Laura, Ruggeri, Enzo Maria, Verusio, Claudio, Gori, Stefania, Bonetti, Andrea, Mosconi, Anna Maria, Johannsson, Oskar, Jerusalem, Guy, Neven, Patrick, Nagy, Tünde, Pinotti, Graziella, Colleoni, Marco A., Bernardo, Antonio, Gianni, Lorenzo, Bucci, Eraldo, Biganzoli, Laura, Dedes, Konstantin, Novak, Urban, Zaman, Khalil, Braybrooke, Jeremy, Winter, Matthew, Rea, Daniel, Kelleher, Muireann, Barrett, Sophie, Chan, Stephen, Hickish, Tamas, Hurwitz, Jane, Conibear, John, Jegannathen, Apurna, Parton, Marina, Tutt, Andrew, Allerton, Rozenn, Borley, Annabel, Armstrong, Anne, Copson, Ellen, Levitt, Nicola, Abraham, Jean, Perren, Timothy, Roylance, Rebecca, Ishida, Kazushige, Toyama, Tatsuya, Masuda, Norikazu, Watanabe, Junichiro, Tokunaga, Eriko, Kinoshita, Takayuki, Rai, Yoshiaki, Takada, Masahiro, Yanagita, Yasuhiro, Nakamura, Rikiya, Nakayama, Takahiro, Naoi, Yasuto, Iwata, Hiroji, Nakamura, Seigo, Takahashi, Masato, Aogi, Kenjiro, Tsugawa, Koichiro, Mukai, Hirofumi, Takano, Toshimi, Osaki, Akihiko, Sato, Nobuaki, Yamauchi, Hideko, Tokuda, Yutaka, Ito, Mitsuya, Sugimoto, Takeki, Bahadur, Shakeela W., Ganz, Patricia A., Lu, Min J., Mita, Monica M., Waisman, James, Polikoff, Jonathan A., Telli, Melinda L., Seaward, Samantha A., Suga, J. Marie, Durna, Lara N., Carney, Jennifer Fu, Menter, Alex, Puthillath, Ajithkumar, Rohatgi, Nitin, Feusner, James H., Bobolis, Kristie A., Eisenberg, Peter D., Wong, Derrick, Borges, Virginia F., Urquhart, Alexander T., Hofstatter, Erin W., McCarron, Edward C., Isaacs, Claudine, Herbolsheimer, Pia, Varadarajan, Ramya, Raben, Adam, Deveras, Ruby Anne E., Valdes-Albini, Frances, Mahtani, Reshma L., Meisel, Jane L., Sumrall, Bradley T., Jones, Cheryl F., Ofori, Samuel N., Sumida, Kenneth N.M., Karwal, Mark, Wilbur, Deborah W., Singh, (Joe), Spector, David M., Schallenkamp, John, Merkel, Douglas E., Lo, Shelly S., Khosla, Pam G., Cristofanilli, Massimo, Flaum, Lisa, Hoskins, Kent F., Cobleigh, Melody A., Lambiase, Elyse A., Hahn, Olwen M., Oliff, Ira A., Faller, Bryan A., Wade, James L., Burhani, Nafisa D., Gil, Amaryllis, Einhorn, Harvey E., Storniolo, Anna M.V., Chang, Brian K., Kalra, Maitri, Robin, Erwin L., Ansari, Bilal, Sharma, Priyanka, Dakhil, Shaker R., Deming, Richard L., Cole, John T., Hanson, David S., Ochoa, Augusto C., Garber, Judy E., Zimbler, Harvey, Armstrong, Deborah K., Tkaczuk, Katherine H.R., Riseberg, David A., O'Connor, Brian M., Openshaw, Thomas H., Zakalik, Dana, Vakhariya, Cynthia M., Schott, Anne F., Simon, Michael S., Doyle, Thomas J., Al Baghdadi, Tareq, VanderWoude, Amy, Flynn, Patrick J., Zera, Richard T., Friday, Bret E.B., Ruddy, Kathryn J., Smith, Ron, Ademuyiwa, Olabisi, Foluso, Ellis, Robert, Carlson, Jay W., Marchello, T, Benjamin, Levine, Edward A., Marcom, Paul K., Harkness, Cameron B., Tan, Antoinette R., Charles, William J., Kuzma, Charles S., Asaad, Shonda, Radford, James E., Steen, Preston D., Unnikrishnan, Madhu, Seeger, Grant R., Leu, Kirsten M.H., Copur, Mehmet S., Hauke, Ralph J., Soori, Gamini S., Arrick, Bradley A., Reeder, Jennifer G., Toppmeyer, Deborah L., Dayao, Zoneddy R., Adams, Sylvia, Andreopoulou, Eleni, Allison, Magnuson, Anampa Mesias, Jesus D., Sharma, Ruby, Ramaswamy, Bhuvaneswari, Gerds, Aaron T., Shenk, Robert R., Gross, Howard M., Trehan, Shruti, Razaq, Wajeeha, Mansoor, Abdul H., Hilton, Christie J., Brufsky, Adam M., Huynh, Chanh, Chowdhury, Nabila, Domchek, Susan M., Sigurdson, Elin R., Cescon, Terrence P., Rovito, Marc A., DeNittis, Albert S., Vogel, Victor G., Julian, Thomas B., Boyle, L.E., Baez-Diaz, Luis, Brescia, Frank J., Doster, John E., Siegel, Robert D., Wong, Lucas, Patel, Tejal, Nangia, Julie R., Jones, Catherine A., Cannon, George M., Bear, Harry D., Vachhani, Hetal, Wilkinson, Mary, Wood, Marie E., Yan, Fengting, Sui, Xingwei, van Haelst, Carol M., Specht, Jennifer M., Zhuo, Ying, Qamar, Rubina, Ryan, Matthew L., Stockham, Abigail, Virani, Shamsuddin, Gayle, Arlene A., Jubelirer, Steven J., Kurian, Sobha, Salkeni, Mohamad A., Loman, Niklas, Linderholm, Barbro, Silander, Gustav, Hallbeck, Anna-Lotta, von Wachenfeldt Väppling, Anna, Curtit, Elsa, Cardoso, Catarina, Braga, Sofia, Abreu, Miguel, Casa-Nova, Mafalda, Nave, Mónica, Ciruelos Gil, Eva María, Gelpi, Judith Balmaña, Ortega, Adela Fernández, Padró, Josep Gumà, Bermejo de las Heras, Begoña, Cao, María González, Bañuelos, Juan Cueva, Company, Jesús Alarcon, Villaró, Gemma Viñas, Estevez, Laura García, Huober, Jens, Busch, Steffi, Fehm, Tanja, Hahn, Antje, Grafe, Andrea, Noesselt, Thomas, Dewitz, Thomas, Wagner, Harald, Bechtner, Christina, Weigel, Michael, Kolberg, Hans-Christian, Decker, Thomas, Thomalla, Jörg, Hesse, Tobias, Harbeck, Nadia, Jens-Uwe Blohmer, Jan Schröder, Wolf Sütterlin, Marc, Altena, Renske, Chiu, Chang-Fang, Chen, Shin-Cheh, Hou, Ming-Feng, Chang, Yuan-Ching, Chen, Shang-Hung, Chen, Shou-Tung, Huang, Chiun-Sheng, Yeh, Dah-Cherng, Yu, Jyh-Cherng, Tseng, Ling-Ming, Chung, Wei-Pang, Mailliez, Audrey, Petit, Thierry, Delaloge, Suzette, Lévy, Christelle, Dalivoust, Philippe, Extra, Jean-Marc, Mouret-Reynier, Marie-Ange, Hardy-Bessard, Anne-Claire, Simon, Hélène, L'Haridon, Tiffenn, Mege, Alice, Giacchetti, Sylvie, Chakiba-Brugere, Camille, Gratet, Alain, Pottier, Virginie, Ferrero, Jean-Marc, Tennevet, Isabelle, Perrin, Christophe, Canon, Jean-Luc, Joris, Sofie, Shao, Zhimin, Xu, Binghe, Jiang, ZeFei, Sun, Qiang, Shen, Kunwei, Pang, Da, Zhang, Jin, Wang, Shui, Yang, Hongjian, Liao, Ning, Zheng, Hong, Fu, Peifen, Song, Chuangui, Wang, Yongsheng, Fan, Zhimin, Geng, Cuizhi, Tredan, Olivier, Landherr, László, Kaufman, Bella, Yerushalmi, Rinat, Uziely, Beatrice, Conte, Pierfranco, Zamagni, Claudio, Bianchini, Giampaolo, De Laurentiis, Michelino, Tondini, Carlo, Gebbia, Vittorio, Ciccarese, Mariangela, Sarosiek, Tomasz, Mackiewicz, Jacek, Słowińska, Anna, Kalinka, Ewa, Huzarski, Tomasz, Im, Seock-Ah, Jung, Kyung Hae, Sohn, Joo Hyuk, Kim, Jee Hyun, Lee, Keun Seok, Park, Yeon Hee, Lee, Kyoung Eun, Chae, Yee Soo, Cho, Eun Kyung, Geyer, C.E., Jr., Garber, J.E., Gelber, R.D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A.C., Arnedos, M., Balmaña, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S.M., Eisen, A., Elsafy, F., Fein, L.E., Fielding, A., Ford, J.M., Friedman, S., Gelmon, K.A., Gianni, L., Gnant, M., Hollingsworth, S.J., Im, S.-A., Jager, A., Jóhannsson, Ó. Þ, Lakhani, S.R., Janni, W., Linderholm, B., Liu, T.-W., Loman, N., Korde, L., Loibl, S., Lucas, P.C., Marmé, F., Martinez de Dueñas, E., McConnell, R., Phillips, K.-A., Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C.F., Španić, T., Stickeler, E., Toi, M., Traina, T.A., Viale, G., Zoppoli, G., Park, Y.H., Yerushalmi, R., Yang, H., Pang, D., Jung, K.H., Mailliez, A., Fan, Z., Tennevet, I., Zhang, J., Nagy, T., Sonke, G.S., Sun, Q., Parton, M., Colleoni, M.A., Schmidt, M., Brufsky, A.M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., and Tutt, A.N.J.

Published
2022
Full Text
View/download PDF

20. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Author

Cho, Byoung Chul, Han, Ji-Youn, Kim, Sang-We, Lee, Ki Hyeong, Cho, Eun Kyung, Lee, Yun-Gyoo, Kim, Dong-Wan, Kim, Joo-Hang, Lee, Gyeong-Won, Lee, Jong-Seok, Shim, Byoung Yong, Kim, Jin-Soo, Chun, Sang Hoon, Lee, Sung Sook, Kim, Hye Ryun, Hong, Min Hee, Ahn, Jin Seok, Sun, Jong-Mu, Lee, Youngjoo, Lee, Dae Ho, Kang, Ji Ah, Lee, NaMi, Kwon, Mi-Jung, Espenschied, Carin, Yablonovitch, Arielle, and Ahn, Myung-Ju

Published
2022
Full Text
View/download PDF

21. Independent domination versus packing in subcubic graphs.

Author

Cho, Eun-Kyung and Kim, Minki

Abstract

In 2011, Henning, Löwenstein, and Rautenbach observed that the domination number of a graph is bounded above by the product of the packing number and the maximum degree of the graph. In this paper, we prove a stronger statement in subcubic graphs: The independent domination number is at most three times the packing number. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer...

Author

Sohn, Joohyuk, Kim, Gun Min, Jung, Kyung Hae, Jeung, Hei-Cheul, Lee, Jieun, Lee, Keun Seok, Im, Seock-Ah, Kang, Seok Yun, Kim, Se Hyun, Kim, Han Jo, Park, Kyong Hwa, Chae, Yee Soo, Koh, Su-Jin, Cho, Eun Kyung, Park, Keon Uk, Lee, Sung Sook, Kim, Ji-Yeon, Choi, In Sil, Baek, Sun Kyung, and Moon, Yong Wha

Published
2024
Full Text
View/download PDF

26. 797 Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2 negative metastatic breast cancer

Author

Park, Changhee, primary, Suh, Koung Jin, additional, Kim, Se Hyun, additional, Im, Seock-Ah, additional, Kim, Min Hwan, additional, Jeong, Jae Ho, additional, Lee, Kyoung Eun, additional, Park, Yeon Hee, additional, Kim, Hee-Jun, additional, Cho, Eun Kyung, additional, Choi, In Sil, additional, Noh, Seung-Jae, additional, Shin, Inkyung, additional, Cho, Dae-Yeon, additional, and Kim, Jeehyun, additional

Published
2023
Full Text
View/download PDF

28. Table S2 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Author

Gray, Jhanelle E., primary, Okamoto, Isamu, primary, Sriuranpong, Virote, primary, Vansteenkiste, Johan, primary, Imamura, Fumio, primary, Lee, Jong Seok, primary, Pang, Yong-Kek, primary, Cobo, Manuel, primary, Kasahara, Kazuo, primary, Cheng, Ying, primary, Nogami, Naoyuki, primary, Cho, Eun Kyung, primary, Su, Wu Chou, primary, Zhang, Guili, primary, Huang, Xiangning, primary, Li-Sucholeiki, Xiaocheng, primary, Lentrichia, Brian, primary, Dearden, Simon, primary, Jenkins, Suzanne, primary, Saggese, Matilde, primary, Rukazenkov, Yuri, primary, and Ramalingam, Suresh S., primary

Published
2023
Full Text
View/download PDF

33. Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia

Author

Park, Young Hoon, primary, Kim, Dae-Young, additional, Mun, Yeung-Chul, additional, Cho, Eun Kyung, additional, Lee, Jae Hoon, additional, Jo, Deog-Yeon, additional, Kim, Inho, additional, Yoon, Sung-Soo, additional, Park, Seon Yang, additional, Kim, Byoungkook, additional, Bang, Soo-Mee, additional, Kim, Hawk, additional, Min, Young Joo, additional, Park, Jae Hoo, additional, Seo, Jong Jin, additional, Moon, Hyung Nam, additional, Lee, Moon Hee, additional, Kim, Chul Soo, additional, Lee, Won Sik, additional, Chong, So Young, additional, Oh, Doyeun, additional, Zang, Dae Young, additional, Lee, Kyung Hee, additional, Hyun, Myung Soo, additional, Kim, Heung Sik, additional, Kim, Sung-Hyun, additional, Kwon, Hyukchan, additional, Kim, Hyo Jin, additional, Park, Kyung Tae, additional, Bae, Sung Hwa, additional, Ryoo, Hun Mo, additional, Choi, Jung Hye, additional, Ahn, Myung-Ju, additional, Yoon, Hwi-Joong, additional, Nam, Sung-Hyun, additional, Kim, Bong-Seog, additional, and Seong, Chu-Myong, additional

Published
2022
Full Text
View/download PDF

35. A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).

Author

Kim, Se Hyun, primary, Suh, Koung Jin, additional, Im, Seock-Ah, additional, Lee, Kyung-Hun, additional, Kim, Min Hwan, additional, Sohn, Joohyuk, additional, Park, Yeon Hee, additional, Kim, Ji-Yeon, additional, Jeong, Jae Ho, additional, Lee, Kyoung Eun, additional, Choi, In Sil, additional, Park, Kyong Hwa, additional, Kim, Hee Jun, additional, Cho, Eun Kyung, additional, Park, So Yeon, additional, Kim, Milim, additional, and Kim, Jee Hyun, additional

Published
2022
Full Text
View/download PDF

40. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFRT790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Author

Cho, Byoung Chul, Han, Ji-Youn, Kim, Sang-We, Lee, Ki Hyeong, Cho, Eun Kyung, Lee, Yun-Gyoo, Kim, Dong-Wan, Kim, Joo-Hang, Lee, Gyeong-Won, Lee, Jong-Seok, Shim, Byoung Yong, Kim, Jin-Soo, Chun, Sang Hoon, Lee, Sung Sook, Kim, Hye Ryun, Hong, Min Hee, Ahn, Jin Seok, Sun, Jong-Mu, Lee, Youngjoo, Lee, Dae Ho, Kang, Ji Ah, Lee, NaMi, Kwon, Mi-Jung, Espenschied, Carin, Yablonovitch, Arielle, and Ahn, Myung-Ju

Abstract

This integrated analysis of a phase 1/2 study (NCT03046992) evaluated the efficacy and safety of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in patients with advanced EGFRT790M-positive NSCLC after previous EGFR TKI therapy.

Published
2022
Full Text
View/download PDF

41. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

Author

Lee KH, Cho BC, Ahn MJ, Lee YG, Lee Y, Lee JS, Kim JH, Min YJ, Lee GW, Lee SS, Lee KH, Ko YH, Shim BY, Kim SW, Shin SW, Choi JH, Kim DW, Cho EK, Park KU, Kim JS, Chun SH, Wang J, Choi S, and Kang JH

Subjects
Humans, Gefitinib therapeutic use, Quinazolines, ErbB Receptors genetics, ErbB Receptors metabolism, Republic of Korea, Mutation, Protein Kinase Inhibitors adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Morpholines, Pyrazoles, Pyrimidines
Abstract

Purpose: This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC)., Materials and Methods: Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS)., Results: In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment-related AEs occurred with lazertinib than gefitinib., Conclusion: Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results